Interview with Dr. Bhavil Kumar Narola, Director – QCA Biocon Sdn. Bhd Kumar Jeetendra | September 11, 2020 Pharma companies are looking for new ways to boost drug discovery potential, reduce time to market and squeeze costs along the whole value chain- Interview with Dr. Bhavil Kumar Narola, Director – QCA Biocon Sdn. Bhd How would you like to summarise your experience in a few lines for our readers? Coaching is the process …
Interview with Mr. Deepak Parab Managing Director Metrohm India Private Limited Kumar Jeetendra | September 11, 2020 I have been involved in every stage of evolution of this organization. Today we have approximately 225 employees and we have been able to increase our sales substantially. In last ten years as CEO and MD, I have mainly focused on couple of thing’s, customer and profitability-Interview with Mr. Deepak Parab Managing Director Metrohm India …
Granules India arm gets USFDA gesture for ADHD treatment drug Kumar Jeetendra | September 11, 2020 New Delhi, Sep 11 (PTI) Medication firm Granules India Friday said its subsidiary has received marketing approval from the US health regulator for Dexmethylphenidate HCl extended-release capsules, used for the treatment of attention-deficit hyperactivity disorder (ADHD). The approved product is bioequivalent to the reference listed drug Focalin XR of Novartis AG. In a BSE filing, …
Zydus Cadila gets USFDA gesture to showcase its disease treatment infusion Kumar Jeetendra | September 11, 2020 New Delhi, Sep 11 (PTI) Medication firm Zydus Cadila on Friday said it has received final nod in the US health regulator to advertise its generic Doxorubicin Hydrochloride Liposome injection, used for treatment of certain types of cancer, in the American market. The company has received final approval from the United States Food and Drug …
Dr. U S Vishal Rao shares deeper insights into the ICMR PLACID trial research on plasma therapy Kumar Jeetendra | September 11, 2020 Bengaluru, 11th September 2020 – The recent study conducted by the Indian Council of Medical Research (ICMR) stated that using plasma therapy for COVID-19 claims that the therapy neither reduces the death risk nor does it slow down the disease’s progression from mild to severe stage. HealthCare Global Enterprises Limited (HCG) – largest cancer care …
Merck begins enrollment for COVID-19 vaccine preliminary Kumar Jeetendra | September 12, 2020 United States drugmaker Merck & Co Inc has begun recruiting participants into its early-stage COVID-19 vaccine study, according to the government database clinicaltrials.gov. The phase 1/2 trial, which is based in Belgium, intends to recruit 260 healthy participants to check the experimental vaccine V591, which it gained access to as a member of its May …
Bharat Biotech States Covaxin generated Strong immune response in monkeys Kumar Jeetendra | September 12, 2020 Bharat Biotech announced its prospective COVID-19 vaccine — Covaxin — was discovered to generate strong immune responses in rhesus macaques or monkeys, preventing infection and disease even upon high levels of exposure to live SARS-CoV-2 virus. The Hyderabad-based firm said data from the study on primates substantiate the immunogenicity of the vaccine candidate. Covaxin developed …
DCGI orders Serum Institute of India to suspend enrollment for Oxford COVID-19 immunization preliminaries Kumar Jeetendra | September 12, 2020 Drugs Controller General of India (DCGI) has led Serum Institute of India to suspend until further orders new recruitment in stage 2 and 3 clinical trials of the Oxford COVID-19 vaccine candidate in the backdrop of pharma giant AstraZeneca pausing the trials in different countries. In an order, a copy of which was obtained by …
Asia offers more influenza shots to take off COVID-19 difficulties Kumar Jeetendra | September 14, 2020 Some Asian countries are rolling out early and more competitive influenza vaccination programs this year, seeking to decrease the capacity of people contracting the flu and COVID-19 simultaneously, crippling health care systems. With a second or third wave of the coronavirus pandemic looming for many countries, tackling this year’s flu season – typically December through …
PC planned antiviral proteins restrain COVID-19 in lab, researchers find Kumar Jeetendra | September 14, 2020 Computer-designed synthetic antiviral proteins have been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19, scientists say. From the experiments, the lead antiviral candidate, called LCB1, rivalled the best-known SARS-CoV-2 neutralising antibodies in its protective activities, according to the findings published in the journal Science. The researchers at the University of …
A few immunosuppressants don’t build COVID-19 risk: Scientists Kumar Jeetendra | September 15, 2020 Therapeutics which suppress the immune system in people who have inflammatory diseases like psoriasis and rheumatoid arthritis”are not associated with a significantly greater risk” for contracting COVID-19, according to a study which says these patients should continue taking their medicine as prescribed. Dermatology researchers in the Henry Ford Health System in the US, which treats …
Aurobindo Pharma ties up with BIRAC to create COVID-19 antibody Kumar Jeetendra | September 15, 2020 Aurobindo Pharma on Tuesday announced collaboration with the Biotechnology Industry Research Assistance Council (BIRAC), set up by the Department of Biotechnology for the development of COVID-19 vaccine. BIRAC has facilitated the establishment of’the r-VSV vaccine’ manufacturing platform for the first time in India by encouraging Aurobindo Pharma’s COVID-19 vaccine development, the company said in a …
